In September 2024 MBX Biosciences raised about $188 million at $16 per share (currently trading at about $10), and in October, BioAge Labs raised $283 million in an IPO at $18 per share (currently trading at about $5 per share after losing 75% of its value in December)
This growth was driven by strong demand across all regions, particularly in the US, where sales amounted to $3.29 billion, reflecting a 57% increase
Possible side effects include: The long-term safety of GLP-1 receptor agonists has not yet been established
Added tips to encourage copper to block DHT: Copper peptides are powerful, but they function best when your entire body is taken care of
However, if you have cancerous cells, EGF will help them to spread, just like it helps healthy cells
The line just fits right into my current skin-care routine